INT-747 , 98% , 459789-99-2

Synonym(s):
(3α,5β, 6α,7α)-6-ethyl-3,7-dihydroxy-cholan-24-oic acid;6a-Ethyl-Chenodeoxycholic Acid;6-ECDCA;OCA

CAS NO.：459789-99-2

Empirical Formula: C26H44O4

Molecular Weight: 420.63

MDL number: MFCD16621104

EINECS: 810-245-2

PRODUCT Properties

• Melting point: 108-110 °C
• Boiling point: 562.9±25.0 °C(Predicted)
• Density: 1.091
• storage temp.: -20°C
• solubility: Soluble in DMSO (up to 35 mg/ml) or in Ethanol (up to 25 mg/ml)
• form: White solid.
• pka: 4.76±0.10(Predicted)
• color: White
• Stability: Stable for 2 years from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 2 months.

Description and Uses

Obeticholic acid is a potent and selective farnesoid X receptor agonist that promotes the flow of bile in the liver. The drug was approved by the USFDA for the treatment of the rare chronic liver disease primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with inadequate response to UDCA or as a single agent therapy in adults unable to tolerate UDCA. Obeticholic acid was discovered at the Università de Perugia and developed by Intercept Pharmaceuticals. Obeticholic acid has also been granted orphan drug designation for the treatment of primary sclerosing cholangitis and primary biliary cirrhosis and has received breakthrough therapy designation for the treatment of patients with nonalcohol steatohepatitis (NASH) with liver fibrosis.

6-Ethylchenodeoxycholic Acid is a derivative of the bile acid Chenodeoxycholic Acid (C291900). 6-Ethylchenodeoxycholic Acid is a potent activator of the farnesoid X nuclear receptor which reduces liver fat and fibrosis in animal models of fatty liver disease.

Safety

• Symbol(GHS): GHS07
• Signal word: Warning
• Hazard statements: H315-H319-H335
• Precautionary statements: P261-P305+P351+P338
• HS Code: 2918199890